Optimizing drug development with novel liver models and a sustainable preservation technology

DefiniGEN (Cambridge, UK), a company developing iPSC-derived human disease models, and Atelerix (Newcastle, UK), a company developing preservation solutions, recently collaborated to successfully ship in vitro liver models from the UK to the USA without freezing or cryopreserving. In this interview, we talk to Heidi Kingdon Jones (left), Chief Business Officer of DefiniGEN, and Alastair Carrington (right), CEO of Atelerix, about how both technologies work, the potential impact on  drug discovery and development and how collaborations like this help work toward a more sustainable future. What sort of models are DefiniGEN’s liver models? How were they developed? Heidi: Our liver...